Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
In vivo and ex vivo complement activation with first exposure to complement-reactogenic anticancer drugs
NL-OMON56981Recruiting
- Sponsor
- Centre for Human Drug Research
- Start
- Nov 2024
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Open-label trial of paclitaxel and pegylated liposomal doxorubicin in breast cancer and ovarian cancer (3 arms), sponsored by Centre for Human Drug Research. Primary endpoints: Plasma C3a, Plasma C3d and 2 more. Started Nov 2024; status: recruiting.
02
Drugs
paclitaxelpegylated liposomal doxorubicin
03
Conditions
breast cancerovarian cancer
Beyond the preview
Go deeper on NL-OMON56981.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56981.